StockData

Liminatus Pharma, Inc. (LIMN) shareholders

LIMNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as LIMNW
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 2/30
$2.81−0.16 (-5.39%)

Close on Nov 17, 2026Market cap $188.72MP/E –Yield –

Ownership

Who owns Liminatus Pharma's shares

Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Chris Kim
Joint filing with Valetudo Therapeutics LLC (14.30%)
9,617,95414.30%13D (active) amendmentJul 2, 2026
Iris Acquisition Holdings LLC6,900,00026.50%13D (active)Apr 30, 2025
Ewon Comfortech Co., Ltd.5,500,00010.90%13G (passive) amendmentJun 24, 2026
KH Feelux Co., Ltd4,000,00015.40%13G (passive)Apr 30, 2025
Samda Biolab Co., Ltd.3,426,5485.10%13G (passive)Jul 2, 2026
Nongae Apple Association 1st1,470,0005.70%13G (passive)Apr 30, 2025
Red Peony Association 1st1,470,0005.70%13G (passive)Apr 30, 2025

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares ownedLatest filing
Chris KimChief Executive Officer, Director, 10% owner6,169,406Jul 14, 2026
Beom Kyu ChoiChief Technology Officer–Apr 30, 2025
Scott DamChief Financial Officer–Apr 30, 2025
Sang-Jin LeeHead of Research & Development–Apr 30, 2025
Byong Chul YooChief Science Officer–Apr 30, 2025
II Philip Wayne LemonsDirector–Jul 23, 2025
Richard JaiHwan BaekDirector–Jul 21, 2025
Eun Sook LeeDirector–May 1, 2025
Nicholas FernandezDirector–Apr 30, 2025
Ji Yeon BaekDirector–Apr 30, 2025
Therapeutics LLC Valetudo10% owner5,244,351Jul 14, 2026
Ewon Comfortech Co., Ltd.10% owner5,500,000Jul 6, 2026
Acquisition Holdings LLC Iris10% owner6,900,000Aug 15, 2025
KH Feelux Co., Ltd10% owner4,000,000Jun 27, 2025

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Therapeutics LLC Valetudo
10% owner
Jul 2, 2026Other+3,448,926––5,244,351
Therapeutics LLC Valetudo
10% owner
Jun 24, 2026Other−4,373,603––1,795,803

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of shares outstanding
–
0M shares short
Days to cover
1.6
At 0M shares a day
Change since last report
+20.9%
From 0M shares
Short volume, 20 days
41.6%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Liminatus Pharma's stock actually held short. Settlement fails (shares not delivered on time) peaked at 12,242 shares on Aug 26, 2026 over the last 90 days.

See a number that looks wrong?